Skip to main content
Log in

Sulphasalazine in the treatment of children with chronic arthritis

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

The ainich of study was to investigate the efficacy and toxicity of sulphasalazine (SASP) in the treatment of children with chronic arthritis. The medical records of 36 children (25 boys, 11 girls) who received SASP for the treatment of chronic arthritis were reviewed. Twenty-one patients had juvenile spondyloarthropathies (JSA) (eight juvenile ankylosing spondylitis (JAS), 13 undifferentiated JSA (uJSA) and 15 had juvenile rheumatoid arthritis (JRA). The patients received SASP therapy for a mean of 2.5 years (range 3 weeks to 8.1 years). Clinical and laboratory data were reviewed retrospectively to determine the effects of treatment. A clinically significant response occurred in 23 (64%) children: remission in 14 (39%) (JRA 5, JSA 9) and improvement (25% reduction in joint count) in nine (25%) (JRA 4, JSA 5). There was no difference in response rate between JR and JSA patients (p=0.11), but the time to remission shorter in JSA patients (mean 5 months) JRA patients (mean 25 months) (p=0.024). Twelve of the 36 patients discontinued non-steroidal anti-inflammatory drugs, and six of eight patients discontinued prednisolone. A significant fall in erythrocyte sedimentation rate and rise in haemoglobin occurred in SASP-treated patients (p<0.005) comparing most recent results with pretreatment levels. Side-effects occurred in four of 36 patients (11%); only one patient who had persisting severe diarrhoea required discontinuation of SASP. It was concluded that SASP appears to be effective and safe in the treatment of JRA and JSA patients. As a second-line agent, SASP is the drug of first choice for patients with JSA; for JRA patients SASP may be a useful, possibly less toxic alternative to methotrexate.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. McConkey B, Amos RS, Butcher RA, et al. Sulphasalazine in rheumatoid arthritis. Br Med J 1980;279:442–4.

    Google Scholar 

  2. Neumann VC, Grundulis KA, Hubball S, et al. Comparison between penicillamine and sulphasalazine in rheumatoid arthritis. Br Med J 1983;287:1099–102.

    Google Scholar 

  3. Bax DE, Amos RS. Sulphasalazine: a safe effective agent for prolonged control of rheumatoid arthritis: a comparison with sodium aurothiomalate. Ann Rheum Dis 1985;44:194–8.

    PubMed  Google Scholar 

  4. Nissila M, Lehtinen K, Leirisalo-Repo M, Luukhainen R, Mutru O, Yli-Kertula U. Sulphasalazine in the treatment of ankylosing spondylitis. Arthritis Rheum 1988;31:1111–6.

    PubMed  Google Scholar 

  5. Kirwan J, Edwards A, Huitfeldt B, Thompson P, Currey H. The course of establishing ankylosing spondylitis and the effects of sulphasalazine over 3 years. Br J Rheumatol 1993;32:729–33.

    PubMed  Google Scholar 

  6. Dougados M, Boumier P, Amor B. Sulphasalazine in ankylosing spondylitis: a double blind controlled study in 60 patients. Br Med J 1986;293:911–4.

    Google Scholar 

  7. Pullar T, Hunter JA, Capell HA. Sulphasalazine in rheumatoid arthritis: a double blind comparison of sulphasalazine with placebo and sodium aurothiomalate. Br Med J 1983;287:1102–4.

    Google Scholar 

  8. Pinala RS, Kaplan SB, Lawson JG, Hepburn B. Sulfasalazine in rheumatoid arthritis: a double-blind, placebo-controlled trial. Arthritis Rheum 1986;29:1427–34.

    PubMed  Google Scholar 

  9. Williams HJ, Ward JR, Dahl SL, et al. A controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis. Arthritis Rheum 1988;31:702–13.

    PubMed  Google Scholar 

  10. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis: results of two metaanalysis. Arthritis Rheum 1990;33:1449–61.

    PubMed  Google Scholar 

  11. Nuver-Zwart IH, van Riel PLCM, van de Putte LBA, Gribnau FWJ. A double blind comparative study of sulphasalazine and hydroxychloroquine in rheumatoid arthritis: evidence of an earlier effect of sulphasalazine. Ann Rheum Dis 1989;48:389–95.

    PubMed  Google Scholar 

  12. Wijnands MJH, van Hof MA, van Leeuwen MA, van Rijswijle MH, van de Putte LBA, van riel PLCM. Long-term second-line treatment: a prospective drug survival study. Br J Rheumatol 1992;31:253–8.

    PubMed  Google Scholar 

  13. Hannonen P, Mottonen T, Hakola M, Oka M. Sulfasalazine in early rheumatoid arthritis: a 48-week double-blind, prospective, placebo-controlled study. Arthritis Rheum 1993;36:1501–9.

    PubMed  Google Scholar 

  14. Ozdogan H, Turuns M, Deringol B, Yurdakul S, Yazici H. Sulphasalazine in the treatment of rheumatoid arthritis: a preliminary open trial. J Rheumatol 1986;13:124–5.

    PubMed  Google Scholar 

  15. Imundo LF, Jacobs JC. Treatment of juvenile arthritis (JA) with sulphasalazine. Arthritis Rheum 1993;36(suppl):s122.

    Google Scholar 

  16. Joos R, Veys EM, Mielants H, van Werveke S, Goemaere S. Sulfasalazine treatment in juvenile chronic arthritis: an open study. J Rheumatol 1991;18:880–4.

    PubMed  Google Scholar 

  17. Ansell BM, Hall MA, Loftus JK, et al. A multicenter pilot study of sulphasalazine in juvenile chronic arthritis. Clin Exp Rheumatol 1991;9:201–3.

    PubMed  Google Scholar 

  18. Job-Deslandre C, Menkes CJ. Sulphasalazine in the treatment of juvenile spondyloarthropathy. Arthritis Rheum 1991;34 (suppl):s153

    PubMed  Google Scholar 

  19. Susche HJ. Treatment of juvenile spondyloarthritis and reactive arthritis with sulphasalazine. Monatsschr Kinderheilkd 1992;140:658–60.

    PubMed  Google Scholar 

  20. Burgos-Vargas R, Pacheco-Tena C, Vazguez-Mellado J. Juvenileonset spondyloarthropathy. Rheum Dis Clin North Am 1997;23:569–99.

    PubMed  Google Scholar 

  21. Brewer EJ, Bass J, Baum J, et al. Current proposed revision of JRA criteria. Arthritis Rheum 1977;20(suppl):195–9.

    PubMed  Google Scholar 

  22. Bennett BH, Birch TA. New York symposium on population studies in the rheumatic diseases: new diagnostic criteria. Bull Rheum Dis 1967;25:1041–7.

    Google Scholar 

  23. Rosenberg AM, Petty RE. A syndrome of seronegative enthesopathy and arthropathy in children. Arthritis Rheum 1982;25:1041–7.

    PubMed  Google Scholar 

  24. Cabral DA, Oen Kg, Petty RE. SEA syndrome revisited: a longerm follow-up of children with a syndrome of seronegative enthesopathy and arthropathy. J Rheumatol 1992;19:1282–5.

    PubMed  Google Scholar 

  25. Burgos-Vargas R, Clark P. Axial involvement of the seronegative enthesopathy and arthropathy syndrome and its progression to ankylosing spondylitis. J Rheumatol 1989;16:192–7.

    PubMed  Google Scholar 

  26. Hussein A, Abdul-Khaliq H, von der Hardt H. Atypical spondyloarthritis in children: proposed diagnostic criteria. Eur J Pediatr 1989;148:513–7.

    PubMed  Google Scholar 

  27. Jacobs JC, Berdon WE, Johnston AD. HLA-B27-associated spondyloarthritis and enthesopathy in childhood: clinical, pathologic, and radiographic observations in 58 patients. J Pediatr 1982;100:521–8.

    PubMed  Google Scholar 

  28. Hawkey CJ, Truelove SC. Inhibition of prostaglandin synthetase in human rectal mucosa. Gut 1983;24:213–7.

    PubMed  Google Scholar 

  29. Rhodes JM, Bartholomew TC, Jewell DP. Inhibition of leukocyte motility by drugs used in ulcerative colitis. Gut 1981;22:642–7.

    PubMed  Google Scholar 

  30. Carter SD, Bacon PA, Hall ND. Characterization of activated lymphocytes in the peripheral blood of patients with rheumatoid arthritis. Ann Rheum Dis 1981;40:293–8.

    PubMed  Google Scholar 

  31. Madhok R, Wijelath E, Smith J, Watson J, Sturrock RD, Capell HA. Is the beneficial effect of sulphasalazine due to inhibition of synovial neovascularization? J Rheumatol 1991;18:199–202.

    PubMed  Google Scholar 

  32. Greenfield SM, Hamblin AS, Shakoor ZS, Teare JP, Punchard NA, Thompson RPH. Inhibition of leukocyte adhesion molecule upregulation by tumor necrosis factor: a novel mechanism of action of sulphasalazine. Gut 1993;34:256–6.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huang, JL., Chen, LC. Sulphasalazine in the treatment of children with chronic arthritis. Clin Rheumatol 17, 359–363 (1998). https://doi.org/10.1007/BF01450892

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01450892

Keywords

Navigation